Immunovant Inc.

09/03/2026 | Press release | Distributed by Public on 09/03/2026 15:06

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On September 2, 2026, Immunovant, Inc. ("Immunovant") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). There were 198,373,370 shares of common stock and Series A preferred stock represented at the Annual Meeting by valid proxies or voted at the Annual Meeting, which was approximately 96% of the shares of common stock and Series A preferred stock entitled to vote at the Annual Meeting. At the Annual Meeting, Immunovant's stockholders voted on the three proposals set forth below. A more detailed description of each proposal is set forth in Immunovant's definitive proxy statement for the Annual Meeting (the "Proxy Statement"), which was filed with the Securities and Exchange Commission on July 22, 2026.
Proposal 1 - Election of Directors
Jacob Bauer, Douglas Hughes and Robert Susman were each elected to serve as a member of Immunovant's Board of Directors (the "Board"), until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified, by the following votes:
Nominee Votes For Votes Withheld Broker Non-Votes
Jacob Bauer 162,872,114 26,430,450 9,070,806
Douglas Hughes 174,053,304 15,249,260 9,070,806
Robert Susman 181,604,476 7,698,088 9,070,806
Proposal 2 - Ratification of the Selection of Independent Registered Public Accounting Firm
The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2027, by the following votes:
Votes For Votes Against Votes Abstain
198,148,265 187,390 37,715
Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers
The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures, by the following votes:
Votes For Votes Against Votes Abstain Broker Non-Votes
180,772,822 8,437,839 91,903 9,070,806
Immunovant Inc. published this content on September 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on September 03, 2026 at 21:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]